CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...
Vertex Pharmaceuticals upgraded to Hold from Sell at Canaccord yesterday
As previously reported yesterday afternoon, Canaccord upgraded Vertex Pharmaceuticals (VRTX) to Hold from Sell with a price target of $424, up ...
Vertex Pharmaceuticals SVP Ambrose sells shares for $632,726
Kristen Ambrose, Senior Vice President and Chief Accounting Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a $116 billion market cap biotechnology company with strong financial health according ...
Vertex Pharma upgraded at Canaccord Genuity after Q4 results
Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.
SpotDraft Secures $54 Million To Lead AI Contract Lifecycle Management
SpotDraft's Series B funding round, spearheaded by Vertex Ventures and Trident Partners, will accelerate the company's global ...
RBC Capital Reaffirms Their Hold Rating on Gilead Sciences (GILD)
In a report released yesterday, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a ...